DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

Detailed Information

Meeting Date:

02/24/2024

DBV Abstract Details:

Oral Abstract Presentation

“A Streamlined Approach to Basophil Activation Testing for Longitudinal Characterization of Toddlers with Peanut Allergy During a Multi-Site Phase 3 Double-Blind Placebo-Controlled Trial of Epicutaneous Immunotherapy (EPIT)” will be presented by Dr. Jean-Marc Busnel (Beckman Coulter)

  • Presentation date: Saturday, February 24, 2024
  • Presentation time: 2:15 p.m. – 2:25 p.m. ET
  • Presentation location: Convention Center, Level 3, Ballroom B

Poster Presentation

“Long-term Safety Results of Epicutaneous Immunotherapy (EPIT) with Viaskin Peanut in Peanut-Allergic Children Aged 4-11 Years in the Phase 3 PEOPLE Study” will be presented by Dr. David Fleischer, Associate Professor of Pediatrics at Children’s Hospital Colorado.

  • Poster number: 379
  • Session title: Treatment and Management of IgE-mediated Food Allergy
  • Presentation date: Saturday, February 24, 2024
  • Presentation time: 9:45 a.m. – 10:45 a.m. ET
  • Presentation location: Convention Center, Level 2, Hall D
Scroll to Top